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Background. During the coronavirus disease 2019 (COVID-19) pandemic, many countries experienced infection in health care 
workers (HCW) due to overburdened health care systems. Whether infected HCW acquire protective immunity against severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) is unclear.
Methods. In a Norwegian prospective cohort study, we enrolled 607 HCW before and after the first COVID-19 wave. Exposure 
history, COVID-19–like symptoms, and serum samples were collected. SARS-CoV-2–specific antibodies were characterized by 
spike-protein IgG/IgM/IgA enzyme-linked immunosorbent and live-virus neutralization assays.
Results. Spike-specific IgG/IgM/IgA antibodies increased after the first wave in HCW with, but not in HCW without, COVID-
19 patient exposure. Thirty-two HCW (5.3%) had spike-specific antibodies (11 seroconverted with ≥4-fold increase, 21 were sero-
positive at baseline). Neutralizing antibodies were found in 11 HCW that seroconverted, of whom 4 (36.4%) were asymptomatic. 
Ninety-seven HCW were tested by reverse transcriptase polymerase chain reaction (RT-PCR) during follow-up; 8 were positive (7 
seroconverted, 1 had undetectable antibodies).
Conclusions. We found increases in SARS-CoV-2 neutralizing antibodies in infected HCW, especially after COVID-19 patient 
exposure. Our data show a low number of SARS-CoV-2–seropositive HCW in a low-prevalence setting; however, the proportion of 
seropositivity was higher than RT-PCR positivity, highlighting the importance of antibody testing.
Keywords.  health care workers; COVID-19; SARS-CoV-2; spike protein; antibody characterization; IgG; IgM; IgA; neutralizing 
antibody; seroconversion.
The novel severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) 
emerged in Wuhan, China in late December 2019 [1]. Cases in-
creased dramatically in January 2020 before a lockdown was im-
plemented, which brought the outbreak under control. However, 
the virus had spread to other countries and Europe became the 
epicenter of the pandemic in March 2020. The high numbers of 
cases and associated mortality overwhelmed health care services 
in Italy [2, 3], leading many countries to implement lockdowns 
to reduce the spread of SARS-CoV-2 and protect their citizens.
Health care workers (HCW) in contact with COVID-19 pa-
tients are at higher risk of occupational infection, up to 11.6-
fold, compared to other HCW and in the community [4–6]. The 
overwhelming hospital admission rates of severely ill patients, 
exhausting the health care resources, have globally resulted 
in thousands of infected HCW [5–9] and hundreds of deaths 
[10–12].
Current testing for SARS-CoV-2 relies on amplification of the 
viral genome using reverse transcriptase-polymerase chain re-
action (RT-PCR) during the acute infection, whereas serological 
assays can determine infection over a longer period. In China, 
17% of HCW were seropositive after exposure to COVID-19 
patients, despite testing negative by RT-PCR [13]. Serological 
assays detecting antibodies to the SARS-CoV-2 spike protein 
and its receptor-binding domain (RBD) provide an important 
tool for examining infection in health care settings [14].
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COVID-19 cases in Norway were first detected on 26 
February 2020 [15] and increased rapidly before a lockdown was 
implemented on 12 March 2020, with the pandemic peaking on 
26 March 2020. The local epidemic period is well defined with 
early and prioritized RT-PCR testing of HCW with COVID-19 
patient exposure or COVID-19–like symptoms. This enabled 
detailed follow-up of infected HCW and determination of the 
extent of undiagnosed asymptomatic or mild illness, which 
can fuel the spread of virus in hospitals and the community. 
In this study, we enrolled 607 HCW before their exposure to 
COVID-19 patients to investigate antibody responses to SARS-
CoV-2, infection rates, and associated risk factors during the 
first COVID-19 pandemic wave in Bergen, Norway.
METHODS
Study Design
We conducted a prospective cohort study of HCW working in 
health care facilities testing and treating COVID-19 patients 
(Bergen Municipality Emergency Room, Haukeland University 
and Haraldsplass Deaconess Hospitals), which was approved by 
the Western Norway Ethics committee (No. 118664). Inclusion 
criteria were HCW with or without present/potential future ex-
posure to COVID-19 patients, and working from 6 March to 
9 April 2020. Exclusion criteria were HCW in quarantine or 
RT-PCR confirmed SARS-CoV-2 infection at recruitment. All 
HCW provided written informed consent before inclusion and 
serum samples were collected at baseline and 6–10 weeks later 
(before and after the peak of the first COVID-19 pandemic 
wave) (Supplementary Figure 1). Sera were coded with a unique 
identification number, aliquoted, and stored at –80°C, and heat-
inactivated for 1 hour at 56°C before use.
Case Report Form
A cloud-based case report form was developed using REDCap 
electronic data capture tools [16] to collect relevant clinical and 
demographic data, such as recent travel history, contact with 
suspected or confirmed COVID-19 patients, use of personal 
protective equipment (PPE), intercurrent illnesses including 
respiratory disease (fever, dry cough, difficulty breathing, sore 
throat, myalgia, malaise, and any other relevant symptoms), 
and RT-PCR results (Table 1).
Antigens and Viruses
The SARS-CoV-2 RBD and spike proteins were produced 
and purified as previously described [14]. The live hCoV-19/ 
Norway/Bergen-01/2020 (GISAID accession ID EPI_
ISL_541970) virus was isolated in house from the throat swabs 
of a Norwegian RT-PCR–confirmed patient and propagated in 
Vero cells before use in neutralization assays.
Enzyme-linked Immunosorbent Assay
Sera were tested in a 2-step enzyme-linked immunosorbent 
assay (ELISA) process: screening ELISA for high-throughput 
detection of RBD-reactive samples followed by a confirm-
atory spike protein ELISA, with minor modifications [14]. 
Paired baseline and follow-up sera (diluted 1:100) were 
tested in duplicates in 96-well plates to detect total im-
munoglobulins (Sigma-Aldrich) binding to the RBD protein 
using 3,3´,5,5´-tetramethylbenzidine (TMB; BDbiosciences). 
A negative control panel of prepandemic sera (n = 128) and 
a positive control panel of RT-PCR–confirmed COVID-19 
patient sera (n  =  43) were used to define the negative and 
positive cutoffs, respectively, based upon the optical den-
sity (OD) at 450/620nm (Supplementary Figure 2). Positive 
(OD  >  0.708) or intermediate (OD  >  0.430) sera detected 
by the screening ELISA were further titrated, starting from 
1:100, to detect IgG (Sigma-Aldrich) binding to the RBD and 
spike proteins. A prepandemic sera pool, a hospitalized pa-
tient serum, and the human monoclonal antibody reactive to 
both SARS-CoV-1 and 2 (CR3022) were used as controls. The 
mean end point titer was calculated for each sample. Positive 
sera with spike-specific IgG end point titers above 3 standard 
deviations of the mean of prepandemic negative control pool 
(>485) were further titrated to detect spike-specific IgM and 
IgA (Sigma-Aldrich). Samples with undetectable antibodies 
were assigned an end point titer of 50 for calculation pur-
pose. HCW were defined as seroconverters if they had ≥4-
fold increase in antibody titers from baseline to follow-up.
Neutralization Assays
Paired baseline and follow-up sera with positive or inter-
mediate results by RBD screening ELISA were tested in the 
microneutralization (MN) assay and positive MN samples were 
further tested in the virus neutralization (VN) assay, performed 
in a certified biosafety level 3 laboratory using the live hCoV-
19/Norway/Bergen-01/2020 virus. 
MN Assay
Briefly, sera were serially diluted, starting from 1:20, and mixed 
with 100 tissue culture infectious dose 50% (TCID50) virus in 
96-well plates. The mixtures were incubated for 1 hour at 37°C 
before transferring to 96-well plates preseeded with Vero cells 
for 24-hour incubation at 37°C. Cells were fixed and perme-
abilized with methanol and 0.6% H2O2 and incubated with 
the anti-SARS-CoV-2 nucleoprotein rabbit monoclonal IgG 
(Sino Biological), then anti-rabbit biotinylated goat IgG (H+L) 
(Southern Biotech), extravidin-peroxidase (Sigma-Aldrich) 
and substrate o-phenylenediamine dihydrochloride (Sigma-
Aldrich). The MN titer was the reciprocal of the serum dilution 
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VN Assay
The VN assay was conducted as for the MN assay, except 
that the serum/virus/cells were incubated for 4–5  days at 
37°C. All wells were examined under a microscope for 
cytopathic effect. The VN titer was determined as the re-
ciprocal of the highest serum dilution giving 100% inhibi-
tion of virus infectivity (no cytopathic effect). Titers <20 
were assigned a value of 10 for calculation purpose.




High Riska  
(n = 383)




Age median ± SD 39 ± 12.6 36 ± 12.6 42.5 ± 12.7   
Age group, y .0096 .8382
 20–50 446 (73.5) 295 (77.0) 151 (67.4)   
 51–78 161 (26.5) 88 (23.0) 73 (32.6)   
Sex .0138 .6269
 Female 468 (77.1) 283 (73.9) 185 (82.3)   
 Male 139 (22.9) 100 (26.1) 39 (17.4)   
Workplace <.0001 .0010
 Haukeland University Hospital 471 (77.6) 247 (64.5) 224 (100)   
 Haraldsplass Deaconess Hospital 54 (8.9) 54 (14.1) …   
 Bergen Municipality Emergency 82 (13.5) 82 (21.4) …   
Profession <.0001 .0347
 Physician 174 (28.7)  126 (32.9) 48 (21.4)   
 Nurse 286 (47.1)  200 (52.2)  86 (38.4)   
 Other 147 (24.2)  57 (14.9)  90 (40.2)   
Travel history in 2020 at baseline .2271 .9452
 International 133/606 (21.9) 91/382 (23.8) 42/224 (18.7)   
 Domestic 38/606 (6.3) 26/382 (6.8) 12/224 (5.3)   
 None 435/606 (71.8) 265/382 (69.2) 170/224 (75.9)   
Occupational exposure at baseline <.0001 .0094
 Confirmed patient contact 37/597 (6.2) 37/379 (9.8) 0/218 (0)   
 Suspected patient contact 74/597 (12.4) 74/379 (19.5) 0/218 (0)   
 No patient contact 486/597 (81.4) 268/379 (70.7) 218/218 (100)   
Occupational exposure at follow-up <.0001 <.0001
 With PPE 263/605 (43.5) 263/381 (69.0) 0/224 (0)   
 Without PPE 10/605 (1.7) 10/381 (2.6) 0/224 (0)   
 No contact 332/605 (54.9) 108/381 (28.3) 224/224 (100)   
Community exposure at follow-up 17/604 (2.8) 15/380 (3.9) 2/224 (0.9) .0283 .4295
Symptoms at follow-up .0920 .3229
 Any symptom 116/606 (19.1) 81/382 (21.1) 35/224 (15.6)   
 Dry cough 59/113 (52.2) 40/78 (51.2) 19/35 (54.3)   
 Fever 29/113 (25.7) 22/79 (27.9) 7/34 (20.1)   
 Dyspnea 22/113 (19.5) 20/79 (25.3) 2/34 (5.9)   
SARS-CoV-2 RT-PCR test at follow-up .9719 .7291
 Positive  8 (1.3) 5 (1.3) 3 (1.3)   
 Negative 89 (14.7) 62 (16.2) 27 (12.1)   
Been in quarantine at follow-up 108/598 (18.1) 74/377 (19.6) 34/221 (15.4) .1928 .1808
Screening anti-RBD SARS-CoV-2 antibodies at baseline .4987 .2401
 Negative 550 (90.6) 343 (89.6) 207 (92.4)   
 Intermediate 46 (7.6) 32 (8.3) 14 (6.2)   
 Positive 11 (1.8) 8 (2.1) 3 (1.4)   
Screening anti-RBD SARS-CoV-2 antibodies at follow-up .5362 .2400
 Negative 542 (89.3) 338 (88.3) 204 (91.1)   
 Intermediate 47 (7.7) 33 (8.6) 14 (6.2)   
 Positive 18 (3.0) 12 (3.1) 6 (2.7)   
Data are No. (%) unless otherwise specified. Bold values are statistically significant values with P < .05.
Abbreviations: COVID-19, coronavirus disease 2019; PPE, personal protective equipment; RBD, receptor-binding domain; RT-PCR, reverse transcription polymerase chain reaction; SARS-
CoV-2, severe acute respiratory syndrome coronavirus 2.
aHigh-risk group that tested and treated COVID-19 patients includes emergency, infectious diseases, and intensive care unit departments at Haukeland University Hospital, Haraldsplass 
Deaconess Hospital, and Bergen Municipality Emergency Room. Low-risk group that did not treat COVID-19 patients includes other clinical departments and laboratories.
bCrude P value was determined by χ 2 test (associations between exposure groups and characteristics) in R.
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Statistics
ELISA end point titers and MN titers were calculated using 
Prism version 8.4.2 (GraphPad). Demographic, clinical charac-
teristics, and serological data of occupationally exposed groups 
were examined using χ 2 tests and adjusted for confounding vari-
ables in generalized mixed-effect models. The odds ratio (OR) 
with 95% confidence interval (CI) was calculated for HCW 
having SARS-CoV-2–specific antibodies. Serological data were 
log-transformed and compared between time points in mixed-
effects models with adjustment for subject variance and con-
founding variables. All statistical analyses were performed in R 
version 4.0.2 and visualized in Prism version 8.4.2. P values < 
.05 were considered statistically significant.
RESULTS
The pandemic period was well defined in Bergen, Norway 
due to early rigorous centralized RT-PCR testing of suspected 
COVID-19 cases, with the first detection of confirmed cases on 
28 February 2020, providing a unique opportunity to study the 
impact of the pandemic on HCW.
Study Population
HCW (n = 607, 77.1% female and median age 39 years, range 
20–78 years) were enrolled from Bergen’s main health care in-
stitutions testing and treating COVID-19 patients, including 
286 nurses (47.1%) and 174 physicians (28.7%) (Table  1). 
Recruitment started from 6 March 2020 before the first hos-
pitalizations (9 March 2020)  and the first death (23 March 
2020)  from COVID-19 (Figure  1A). HCW were followed up 
throughout the first pandemic wave in Bergen (6–10 weeks).
HCW were grouped by their occupational exposure: high-
risk (n  =  383, 63.1%) working at the testing facility or on 
COVID-19–designated wards, and low-risk (n  =  224, 36.9%) 
with no COVID-19 patient exposure (Table  1). We found no 
significant differences in age, sex, or recent travel history be-
































































Figure 1. Screening for SARS-CoV-2 RBD-specific antibodies in HCW before and after COVID-19 patient admissions. A, HCW (n = 607) were recruited between 6 March 
2020 and 9 April 2020, and followed up after 6–10 weeks. Each circle represents 1 HCW and their anti-RBD antibodies measured in the screening ELISA as OD at 450/620 nm 
(left y-axis). The numbers of hospitalized COVID-19 patients (blue line) and cumulative deaths (orange line) in Bergen, Norway are plotted on the right y-axis. Lockdown was 
initiated in Norway on 12 March 2020 and a gradual reopening starting on 20 April 2020. B, HCW were grouped into high risk (testing facility, COVID-19–designated wards, 
and intensive care unit wards) and low risk (no known exposure to COVID-19 patients) of occupational exposure to SARS-CoV-2 according to their working department and in-
formation in their case report forms. Dotted lines are cutoffs for negative screening results (OD < 0.430) and positive screening results (OD ≥ 0.708) (see Supplementary Figure 
1 for further information). Horizontal lines represent mean with standard deviation. OD values were log-transformed and compared between time points in mixed-effects 
models with adjustment for subject variation, age, sex, and other relevant demographic factors. *P < .05. Abbreviations: COVID-19, coronavirus disease 2019; ELISA, enzyme-
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nurses in the high-risk (85.1%) than the low-risk group (59.8%) 
(P = .035). HCW with COVID-19–like illness were prioritized 
for RT-PCR testing and 97 (16%) HCW were tested during the 
follow-up period. Only 8 HCW tested positive for SARS-CoV-2 
(5 high-risk and 3 low-risk HCW).
Serology Results
The SARS-CoV-2 virus attaches to the host cells through RBD 
on its spike protein, therefore antibodies binding to these pro-
teins have the potential to block viral entry. Spike- and RBD-
specific antibodies were used in this study to define infection, 
as they do not cross-react with other human coronaviruses [14].
RBD- and Spike-Specific Antibodies
Using screening ELISA, we found that the majority of HCW had 
undetectable antibodies to RBD before and after the first pan-
demic wave (90.6% at baseline and 89.3% at follow-up; Table 1 
and Figure 1A), although the RBD-binding antibody OD values 
were significantly higher at follow-up than at baseline in both 
high-risk (P = .027) and low-risk (P = .034) groups (Figure 1B). 
The RBD-specific IgG levels were measured for HCW with 
positive or intermediate results by screening ELISA (n  =  76, 
12.5%), which were also confirmed by spike protein IgG ELISA 
(Supplementary Figure 3A and 3B). We observed a significant 
increase in RBD-specific IgG geometric mean end point titers 
(GMT) after the first pandemic period (P < .001), from 336 at 
baseline to 637 at follow-up (Figure 2A). This increase was sig-
nificant in the high-risk group (P = .002) but not in the low-risk 
group (Figure 2B). In agreement, a significant increase in spike-
specific IgG GMT was observed after the first pandemic wave 
(P = .002), from 277 at baseline to 518 at follow-up, which was 
only significant in the high-risk group (P = .012; Figure 3A and 
3B and Supplementary Figure 3B). Forty-four HCW (7.2%) had 
RBD-specific IgG above the positive cutoff of 400; 14 were pos-
itive at follow-up (11 seroconverted with ≥4-fold increase and 
3 had <2.5-fold increase in titers) and 30 were positive at both 
baseline and follow-up (Figure 2C). Of these, 32 HCW (5.3%) 
were confirmed seropositive in the spike IgG ELISA with end 
point titers above the positive cutoff of 485; 11 seroconverted 
at follow-up (9/11 in the high-risk group) and 21 were positive 
at baseline (Figure 3C). Notably, 5 HCW (4/5 in the high-risk 
group) had >2-fold increase in IgG titers at follow-up but re-
mained below the positive cutoff.
The spike-specific IgM and IgA antibody levels were meas-
ured in the 32 IgG-seropositive HCW (Figure  4A–4D and 
Supplementary Figure 4A–4D). An increase in both spike-
specific IgM and IgA GMT was observed in HCW after the 
pandemic period, although this was only significant for IgA 
and high-risk HCW (Figure  4C and 4D). The IgM GMT in-
creased from 87 to 159 (P = .068) and the IgA GMT increased 
from 58 to 101 (P  =  .005) from baseline to follow-up in the 
high-risk group (Figure 4B and 4D). Nine HCW had IgM anti-
bodies above the positive cutoff of 300; 7 seroconverted (≥4-
fold increase) at follow-up (6/7 were high-risk HCW) and 2 
were seropositive at baseline (Supplementary Figure 4C). Six 
HCW had IgA antibodies above the positive cutoff of 200; 4 
seroconverted (3/4 were high-risk HCW) and 2 had increases 
in titer but did not seroconvert (<4-fold increase) at follow-up 
from a negative titer at baseline (Supplementary Figure 4D). 
Four HCW in the high-risk group who IgG seroconverted had 
>2-fold increase in either IgM or IgA titers at follow-up but re-
mained below the positive cutoff.
Neutralizing Antibodies
Virus neutralizing antibodies can potentially prevent rein-
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Figure 2. SARS-CoV-2 RBD-specific IgG antibodies in HCW before and after COVID-19 patient admissions. A, The RBD-specific IgG end point titers were measured for HCW 
with positive or intermediate RBD screening results (n = 76) by ELISA. B, RBD-specific IgG end point titers in high-risk and low-risk HCW groups. C, HCW were divided into 
seroconverters (blue circle) who were seropositive and had ≥4-fold increase in IgG titers at follow-up and nonseroconverters (gray circle) who were either seronegative or 
had <4-fold increase in IgG titers at follow-up. The fold changes are plotted on the right y-axis with horizontal lines representing the mean with standard error of the mean. 
Dotted lines represent cutoffs for positive results, calculated as 3 standard deviations above the mean of the prepandemic negative sera (RBD IgG end point titer ≥400). 
Individuals with undetectable antibodies were assigned an end point titer of 50 for plotting and calculation purposes. End point titers were log-transformed and compared 
between time points in mixed-effects models with adjustment for subject variation, age, sex, and other relevant demographic factors. **P < .01, ***P < .001. Abbreviations: 
COVID-19, coronavirus disease 2019; ELISA, enzyme-linked immunosorbent assay; HCW, health care workers; IgG, immunoglobulin G; RBD, receptor-binding domain; SARS-
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assessed in vitro protective immunity against SARS-CoV-2 in 
HCW with positive or intermediate results by screening RBD 
ELISA (n = 76) using the MN assay to confirm infection. The 
MN titers increased significantly from baseline to follow-up 
(P  =  .002; Figure  5A). MN antibodies were found in the 11 
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Baseline to follow-up
Figure 3. SARS-CoV-2 spike-specific IgG antibodies in HCW before and after COVID-19 patient admissions. A, The RBD-specific IgG levels were measured for HCW with 
positive or intermediate RBD screening results (n = 76), which were confirmed in a confirmatory spike IgG ELISA. B, Spike-specific IgG end point titers in high-risk and low-risk 
HCW groups. C, HCW were divided into seroconverters (blue circle) who were seropositive and had ≥4-fold increase in IgG titers at follow-up and nonseroconverters (gray 
circle) who were either seronegative or had <4-fold increase in IgG titers at follow-up. The fold changes are plotted on the right y-axis with horizontal lines representing the 
mean with standard error of the mean. Dotted lines represent cutoffs for positive results, calculated as 3 standard deviations above the mean of the prepandemic negative 
sera (spike IgG end point titer ≥485). Individuals with undetectable antibodies were assigned an end point titer of 50 for plotting and calculation purposes. End point titers 
were log-transformed and compared between time points in mixed-effects models with adjustment for subject variation, age, sex, and other relevant demographic factors. 
*P < .05, **P < .01. Abbreviations: COVID-19, coronavirus disease 2019; ELISA, enzyme-linked immunosorbent assay; HCW, health care workers; IgG, immunoglobulin G; 














































































Figure 4. SARS-CoV-2 spike-specific IgM and IgA antibodies in HCW before and after COVID-19 patient admissions. HCW with positive spike IgG results (n = 32) were 
further analyzed in spike IgM and IgA ELISA. A and C, Spike-specific IgM and IgA end point titers. B, and D, Spike-specific IgM and IgA end point titers in HCW in high-risk 
and low-risk groups. Each circle represents 1 HCW (gray baseline and purple follow-up). Horizontal lines represent geometric mean with 95% confidence interval. Dotted lines 
represent cutoffs for positive results, calculated as 3 standard deviations above the mean of the prepandemic negative sera (IgM end point titer ≥300, IgA end point tire ≥200). 
Individuals with undetectable antibodies were assigned an end point titer of 50 for plotting and calculation purposes. End point titers were log-transformed and compared 
between time points in mixed-effects models with adjustment for subject variation, age, sex, and other relevant demographic factors. *P < .05, **P < .01. Abbreviations: 
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whom 10 seroconverted and 1 had 2.3-fold increase in MN 
titers (Figure 5B).
We further extended our work to investigate the presence of 
sterilizing immunity that provides complete protection against 
SARS-CoV-2 infection in vitro in the 11 MN-positive HCW. 
The VN titers increased significantly from baseline to follow-up 
(P  =  .003), of which 6 HCW had VN antibodies (titer range 
20–40) and 3 seroconverted with ≥4-fold increase in titer at fol-
low-up (Figure 5C and 5D).
Infection Rates and Risk Factors
The overall SARS-CoV-2 seropositive rate was 5.3% (32/607) 
by using our 2-step ELISAs. Twenty-one HCW were seropos-
itive at baseline, suggesting previous exposure to SARS-CoV-2 
before the study, of which 6 had travelled internationally or 
treated confirmed/suspected COVID-19 patients before re-
cruitment and were not tested or RT-PCR negative. The re-
maining 15 HCW did not recall any potential source of 
infection. Eleven HCW seroconverted during follow-up, 
indicating recent SARS-CoV-2 infection. Of these, 7 HCW 
with COVID-19–like symptoms were confirmed by RT-PCR, 
while 1 was RT-PCR negative and 3 HCW were not tested as 
they were asymptomatic (Supplementary Table 1). Interestingly, 
1 RT-PCR–positive asymptomatic HCW did not develop anti-
RBD antibodies. The total infection rate identified by either 
SARS-CoV-2 RT-PCR or serology testing was 2.0% (12/586, ex-
cluding 21 IgG-seropositive HCW at baseline). The infection 
rates by occupational exposure were 2.4% (9/370) in high-risk 
and 1.4% (3/216) in low-risk departments (P = .4). The majority 
of infected HCW in high-risk departments (7/9, 77.8%) were 
young nurses, aged 23–31  years. Three infected HCW (3/7, 
42.9%) reported partial uses of PPE when treating COVID-19 
patients. Among 3 infected HCW in low-risk departments, 2 
had travelled internationally and 1 had community exposure.
Risk factors for SARS-CoV-2 seropositivity at baseline were 
recent travel history (OR, 1.8; 95% CI, .5–7.1), contact with con-
firmed or suspected patients (OR, 1.7; 95% CI, .7–4.3), having 
COVID-19–like symptoms, that is sore throat (OR, 1.9; 95% CI, 
.8–4.3) and myalgia (OR, 1.6; 95% CI, .6–4.3), young age (OR, 
1.5; 95% CI, .7–3.4), and nursing occupation (OR, 1.3; 95% CI, 
.7–2.7) (Supplementary Table 2). At follow-up, HCW using par-
tial PPE when treating COVID-19 patients had 2.5-fold higher 





















































Figure 5. SARS-CoV-2 neutralizing antibodies in HCW. A, MN titers of HCW with positive or intermediate SARS-CoV-2 RBD screening results (n = 76). C, Live VN titers of 
HCW positive with MN antibodies (n = 11). Each circle represents 1 HCW (gray baseline and purple follow-up). Horizontal lines represent geometric mean with 95% confi-
dence interval. HCW were divided into seroconverters (blue circle) who had ≥4-fold increase in (B) MN and (D) VN titers and nonseroconverters (gray circle) who had <4-fold 
increase in titers. Their respective fold changes in MN and VN titers are plotted on the right y-axis with horizontal lines representing the mean with standard error of the 
mean. Dotted lines represent positive neutralizing antibody titers of 20. Individuals with undetectable antibodies were assigned a titer of 10 for plotting and calculation pur-
poses. MN and VN titers were log-transformed and compared between time points in mixed-effects models with adjustment for subject variation, age, sex, and other relevant 
demographic factors. **P < .01. Abbreviations: HCW, health care workers; MN, microneutralization; RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory 
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DISCUSSION
During the COVID-19 pandemic, many countries experienced 
unprecedented increases in hospitalizations, overwhelming 
their health care systems, and rapidly depleting supplies of PPE, 
resulting in thousands of HCW infections and deaths [4, 20, 21]. 
In the UK, Spain, and the Netherlands, 6%–38% of HCW tested 
positive by RT-PCR [20, 22, 23], some requiring hospitalization 
and intensive care unit treatment [22], although most infections 
were community acquired. Here, we show a considerably lower 
SARS-CoV-2 infection rate among frontline HCW during the 
first wave of the pandemic in Bergen, Norway by RT-PCR and 
serological testing (5.3% overall and 2.0% during follow-up), 
probably due to low levels of community infection and strict 
occupational use of PPE. None of the HCW in our study died 
or were hospitalized. There was little overcrowding of emer-
gency rooms and good compliance with infection prevention 
and control (IPC) measures. The early lockdown in Norway, 
implemented on 12 March 2020 before the first national deaths 
on 16 March 2020, contributed to the low number of com-
munity cases and hospitalizations, thus protecting the health 
care system and its most vital asset, the HCW. Recent modeling 
studies have shown that the unprecedented lockdowns have 
dramatically reduced mortality in many countries, preventing 
12  000 deaths in Norway [24, 25]. No excess deaths were re-
ported during the first pandemic wave in Norway, highlighting 
the success of the rapid deployment of effective public health 
responses. The Norwegian experience with early lockdown is 
especially important when compared to countries without or 
with delayed lockdown, which report higher infection and mor-
tality rates in the community and HCW [4, 20, 21].
Several countries reported higher rates of SARS-CoV-2 
infection among HCW treating COVID-19 patients, up to 
11.6-fold increased risk, compared to other HCW or the com-
munity [5, 8, 26, 27]. In agreement, we found that the infec-
tion rate was 1.7-fold higher in HCW with COVID-19 patient 
exposure (2.4%) than in HCW with no exposure (1.4%), al-
though not statistically significant. Unlike many other coun-
tries, Norway did not experience shortages of PPE, although 
the stockpile was alarmingly low. Only 1.7% (10/605) of our 
HCW reported occupational exposure without PPE to 1–2 
COVID-19 patients and/or contact with an infected colleague; 
none of whom were positive by SARS-CoV-2 RT-PCR or se-
rological assays. However, 42.9% (3/7) of seroconverted HCW 
reported having used partial PPE when treating ≥1 COVID-
19 patients. HCW using partial PPE had 2.5-fold higher odds 
of being SARS-CoV-2 seropositive than HCW without patient 
contact. Nurses have a greater occupational exposure than 
other medical staff. Although we cannot exclude community 
infection, Norway had low levels of community spread and 
one of the highest levels of RT-PCR testing in Europe. In the 
UK, 48% of RT-PCR–positive HCW were nurses [23], while we 
found 77.8% (7/9) of seroconverted HCW treating COVID-19 
patients were young nurses (23–31 years old). Indeed, working 
as a young nurse had higher odds of being SARS-CoV-2 se-
ropositive, perhaps due to less experience in IPC measures. 
Better training in IPC for junior staff and ensuring adequate 
availability of PPE in the future will help to prevent the spread 
of SARS-CoV-2 in health care settings.
Serological assays can determine SARS-CoV-2 infection over 
a longer time period than RT-PCR, which can only detect acute 
infection. In our study, only 8 HCW tested positive by RT-PCR, 
one of whom had no symptoms but was tested due to recent 
international travel. In contrast, serological assays identified in-
fection in 32 HCW, of whom 11 HCW seroconverted after the 
first COVID-19 pandemic wave, indicating recent infection. 
Seven seroconverted HCW had COVID-19–like symptoms 
and infection confirmed by RT-PCR; however, 4 seroconverted 
HCW (36.4%) were asymptomatic and either were RT-PCR 
negative or not tested. Similarly, other seroprevalence studies 
also reported asymptomatic and/or not RT-PCR–tested indi-
viduals who were positive by SARS-CoV-2 serology testing [6, 
13, 28, 29]. In asymptomatic cases, T-cell immunity may control 
SARS-CoV-2 infection in the absence of antibodies. The role of 
asymptomatic HCW in SARS-CoV-2 transmission is not clear, 
particularly in nosocomial transmission to vulnerable patients 
and other HCW, with some studies reporting similar viral loads 
[30] and others reporting less infectious virus [31] found in 
asymptomatic than in symptomatic cases. Combined RT-PCR 
and serology testing is crucial to determine infection spread in 
the health care settings and improve IPC.
 Importantly, virus neutralizing antibodies can poten-
tially prevent reinfection with SARS-CoV-2 [17–19]. We 
developed neutralization assays to investigate protective 
antibodies against the live SARS-CoV-2 virus in HCW, which 
most studies have not reported [3–11, 13, 20–22, 26, 32–41]. 
We showed that 11 recently infected HCW had neutralizing 
antibodies, 6 of them had sterilizing immunity in vitro, 
which could provide protection from reinfection by SARS-
CoV-2, perhaps during the second wave of the pandemic. 
Neutralizing antibodies were not detected in 21 HCW who 
were infected before the study with unknown time of infec-
tion. One explanation could be the change in the spike pro-
tein of SARS-CoV-2 viruses. In March 2020, a variant strain 
has replaced the previous SARS-CoV-2 originally isolated in 
Wuhan, China [42]. The 21 HCW infected before the study 
recruitment in March probably were exposed to the strain 
closer to the Wuhan isolate, which may not be recognized 
by our neutralization assays using the more recently isolated 
Norwegian strain. Recent reinfection of a previously con-
firmed SARS-CoV-2 infection highlights the importance of 
measuring neutralizing antibodies [43]. Future studies should 
investigate the correlates of protection of SARS-CoV-2 neu-
tralizing antibodies against reinfection and its longevity to 
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 Home quarantine was introduced in Norway in late 
February for people with mild COVID-19 infection and 
their family members, HCW with close contact to COVID-
19 patients without proper PPE, and travelers returning from 
countries with SARS-CoV-2 infection. Norway had good ad-
herence with household quarantine, which was covered by 
statutory sick pay. Limitations in initial testing capacity led to 
18% of our HCW being quarantined during the study, which 
reduced the available workforce and increased the workload 
for the remaining HCW. As increased RT-PCR testing became 
available, there was a lower threshold for testing of HCW with 
COVID-19–like symptoms and consequently reduced staff 
absenteeism.
The advantages of our prospective cohort study are the 
early recruitment of HCW before the first pandemic wave 
and prior to COVID-19 patient exposure, the use of stringent 
serological assays to define infection, and the investigation 
of neutralizing antibodies to assess protection from reinfec-
tion. Our moderate patient burden may have resulted in lim-
ited exposure but ensured correct characterization of HCW 
exposure as patients were only hospitalized on COVID-
19–designated wards. The low infection rates in Norwegian 
HCW limited the statistical power of our study, thus the OR 
estimates should be interpreted with caution. Although the 
relevance of neutralizing antibodies using Vero cell-based 
in vitro neutralization assays for correlates of protection re-
mains to be determined, neutralizing antibody titers correl-
ated with in vivo protection after SARS-CoV-2 challenge of 
DNA-vaccinated rhesus macaque [44]. Our findings empha-
size the importance of good IPC systems in health care fa-
cilities to isolate patients with suspected infection to reduce 
risk of exposure, and ensure HCW have suitable training and 
access to PPE.
Ensuring the safety of HCW and protecting them from in-
fection, reinfection, and further transmission is one of the most 
important measures to sustain health care services during a 
pandemic. RT-PCR and serological testing of HCW are cru-
cial to prevent infection within the hospital, as the tests com-
plement each other. Our data document low infection rates 
in Norwegian frontline HCW, where the moderate burden of 
patients enabled rational patient management and compliance 
with IPC measures. Neutralizing antibodies were found in all 
infected HCW who seroconverted, which may provide protec-
tion against reinfection, perhaps during the future waves of the 
pandemic. HCW are vital for managing the ongoing outbreak 
and can be protected through timely national or local control of 
the outbreak, access to PPE, and through training in IPC. There 
is an urgent need to understand the most effective measures to 
protect HCW during this pandemic and our study highlights 
the importance of early control measures to protect society and 
the HCW.
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